TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs Platform
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-191192
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AJ11
Additional Details
Documents1
The Department of Energy, through its contractor TRIAD at Los Alamos National Laboratory (LANL), is announcing a technology licensing opportunity for the Bacterial Lipid Nanodiscs Platform. This innovative platform, developed at LANL, is designed to facilitate advanced research into bacterial membranes by enabling the study of entire membrane environments in a controlled, nanoscale format derived directly from native lipid extracts. The primary objective of this technology is to provide researchers and commercial entities with a safer, more accurate, and comprehensive tool for evaluating immunogenic lipids and membrane-associated targets, which are critical for vaccine design, antimicrobial discovery, and the development of therapeutic antibodies targeting conserved bacterial membrane lipids.
The Bacterial Lipid Nanodiscs Platform operates by creating uniform nanoscale discs—approximately 10 nanometers in diameter—from total lipid extracts harvested from bacterial membranes. These lipid mixtures are encapsulated by the membrane scaffold protein MSP1D1, resulting in stable, membrane-like particles that retain the full complement of native bacterial lipids. This approach eliminates the need for synthetic lipids or live cell cultures, thereby reducing safety risks associated with handling high-risk pathogens while preserving the biological context necessary for meaningful scientific insights.
Technically, the platform adapts established nanodisc assembly methods to incorporate heterogeneous, pathogen-derived lipid extracts rather than relying on defined synthetic mixtures. The process involves solubilizing total lipids from a bacterial source, combining them with MSP1D1, and dialyzing under controlled conditions to form discoidal nanoparticles. These particles faithfully represent the membrane environment of the source organism, including amphiphilic molecules that are typically difficult to purify or study in isolation. The technology has been demonstrated using Yersinia pestis, showcasing its ability to capture lipopolysaccharides (LPS) and diverse immunogenic lipids in their native arrangement, thus enabling the evaluation of binding interactions, immune responses, and potential antigenic targets without the hazards of live pathogen handling. Notably, the platform has facilitated the identification of antibodies specific to E. coli LPS and Y. pestis membrane lipids, which are also available for independent licensing.
Key advantages of the Bacterial Lipid Nanodiscs Platform include:
- The creation of membrane-like structures using native bacterial lipids, offering a more realistic and comprehensive lipid environment than synthetic alternatives.
- Enhanced safety by avoiding the need to handle live pathogens.
- Improved assessment of membrane antigens and immune responses.
- Applicability to a wide range of bacterial species through a unified workflow.
- Production of consistent, nanoscale particles suitable for research and development applications.
Potential market applications span life sciences research (membrane biology, immunology), vaccine development (bacterial antigen discovery), drug discovery (membrane-associated targets), diagnostics (lipid biomarker exploration), and biodefense research (safe pathogen characterization).
The technology is currently at Technology Readiness Level (TRL) 3 and is protected by a pending U.S. patent (LA-UR-26-24920). LANL’s licensing program is focused on transitioning such inventions to commercial innovations, offering both exclusive and non-exclusive licensing agreements to established and start-up companies. Interested parties are encouraged to contact the LANL Technology Partnerships Office for further discussion.
This notice is classified under NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology) and Product Service Code AJ11. There are no set-aside requirements associated with this opportunity. The place of performance is Los Alamos, New Mexico, United States.
For more information or to initiate licensing discussions, interested parties should contact Caleb Ledgerwood or Lindsay Augustyn at [email protected]. Additional details and technology search resources are available at https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology and m.lanl.gov/tech-search.
It is important to note that this announcement is a special notice for technology licensing and is not a solicitation for external development services.
Notice details, including attachments and further updates, can be accessed via the official SAM.gov opportunity listing (ID: e5ca482966284e6bbbc2c6e5da267b88).